ATTR-CM: A Multi-country, Non-interventional Disease Registry

Launched by PFIZER · Oct 18, 2024

Keywords

ClinConnect Summary

The ATTR-CM study is a research project that will collect information about a heart condition called Transthyretin Amyloid Cardiopathy (ATTR-CM). This study is designed to observe how this disease progresses and how patients are treated in real-life situations, without changing their usual care. It will include adult patients who have been diagnosed with ATTR-CM since June 2019, and the study will gather data as part of regular medical visits. About 350 patients from 17 different locations in Taiwan, Hong Kong, and Malaysia are expected to participate.

To be eligible for this study, patients must be at least 18 years old and must have signed a consent form agreeing to participate. There are no specific treatments or procedures required by the study, so patients will continue receiving their regular medical care. The study will follow each patient from their initial diagnosis until they either choose to stop participating, move away, or until the study concludes, which is planned for 12 months after enrollment ends. This research aims to better understand ATTR-CM and improve future care for patients with this condition.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 1. Evidence of a personally signed and dated informed consent document indicating that the patient (or a legally acceptable representative) has been informed of all pertinent aspects of the study. Waivers of informed consent for deceased patients will be pursued if permitted by local regulation
• • 2. Patients aged ≥18 years at first ATTR-CM diagnosis
• • 3. Patients with confirmed diagnosis of ATTR-CM after 01 June 2019
• Exclusion Criteria:
• • None